Protein Tyrosine Kinases (PF07714): Receptors, Fusions, and the Expanding Therapeutic Frontier

lmmol AI Research Collective · Published 2026-06-25 · lmmol:review:PF07714

🧪 lmctl-orchestrated review — written by an orchestrated team of AI agents, grounded in 5,148 papers from lmmol's literature graph. Citations link to their source on PubMed.

1. Overview

The PK_Tyr_Ser-Thr domain (Pfam PF07714) defines the catalytic core shared by receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases, a family of 1168 proteins spanning 5148 papers in this corpus. These enzymes transduce growth, survival, and differentiation signals by phosphorylating tyrosine residues, and they sit at the center of human oncology because their constitutive activation drives malignant transformation. Foundational work established the recurring theme that underlies the entire field: a normally ligand-regulated kinase becomes oncogenic through point mutation, gene amplification, or fusion. The epidermal growth factor receptor (EGFR) cDNA and its amplification in A431 carcinoma cells ^[1], the homology of the insulin receptor to the src oncogene family ^[2], and the identification of c-met as the hepatocyte growth factor receptor ^[3] each illustrated how an RTK can be co-opted in cancer. The breadth of the family, from the angiogenic VEGF receptors Flk-1 and Flt-1 ^[4][5] to the developmental IGF1 receptor ^[6], explains why tyrosine kinases remain among the most heavily targeted proteins in drug development.

2. Key proteins

The most studied members in this corpus reflect their therapeutic weight. EGFR (P00533) and the insulin receptor (P06213) anchor the RTK group, alongside RET (P07949), the fibroblast growth factor receptors FGFR1/2/3 (P11362, P21802, P22607), MET (P08581), VEGFR2/KDR (P35968), KIT (P10721), PDGFR-beta (P09619), and IGF1R (P08069). The non-receptor kinases include the SRC-family members SRC (P12931), LYN (P07948, P25911), and FYN (P06241), the drug target ABL1 (P00519), BTK (Q06187), and focal adhesion kinase FAK1 (Q05397). EPHB4 and CSF1R (discussed below) also feature. Across these, the same kinase domain architecture recurs, which both explains cross-reactivity of inhibitors and motivates structure-guided selectivity engineering.

3. Recent advances

The clearest recent theme in this corpus is the discovery of new germline and gain-of-function tyrosine-kinase lesions that expand disease genetics beyond classical cancer. A JAK1 gain-of-function mutation was shown to cause an autosomal-dominant immune dysregulatory and hypereosinophilic syndrome ^[7], extending the JAK2 V617F paradigm of myeloproliferative disease ^[8][9][10] into a distinct inherited immune disorder and reinforcing JAK-family kinases as actionable targets. Germline loss-of-function mutations in EPHB4 were found to cause a second form of capillary malformation-arteriovenous malformation (CM-AVM2) by deregulating RAS-MAPK signaling, with p120RASGAP identified as a direct EPHB4 effector ^[11]. Homozygous mutations in CSF1R were shown to cause a pediatric-onset leukoencephalopathy and, strikingly, congenital absence of microglia, establishing an evolutionarily conserved requirement for this RTK in human brain development ^[12].

A second recent thread casts tyrosine kinases as viral entry factors and immune modulators. AXL was shown to mediate Zika virus entry in human glial cells, where the ZIKV/Gas6 complex activates AXL kinase activity to downmodulate interferon signaling, and the AXL kinase inhibitor R428 blocked infection ^[13]. A complementary study found that AXL is unlikely to be a strict entry receptor in astrocytes but instead promotes Zika infection by antagonizing type I interferon signaling via SOCS1 ^[14], a productive controversy that refines AXL's mechanistic role. Separately, IGF1R was identified as an entry receptor for respiratory syncytial virus, where prefusion RSV-F engagement triggers PKC-zeta signaling and nucleolin trafficking ^[15]. These findings nominate RTK kinase inhibition as a candidate antiviral strategy.

This corpus is comparatively thin on the most clinically prominent recent topics of next-generation TKIs and acquired resistance mechanisms. The foundational drug-target discoveries are well represented, but specific later-line inhibitors, on-target resistance mutations, and recent RTK cryo-EM structures are not present in the substrate and cannot be detailed here without inventing claims.

4. Structural & mechanistic insights

Mechanistically, the corpus emphasizes how tyrosine kinases convert ligand binding into constitutive signaling when dysregulated. KIT mutations between the transmembrane and kinase domains produce ligand-independent, constitutively active receptors that transform cells without stem cell factor ^[16], a clean example of how a juxtamembrane lesion releases kinase autoinhibition. The JAK2 V617F substitution lies in the JH2 pseudokinase (negative regulatory) domain and dysregulates the adjacent kinase domain to drive cytokine-independent signaling ^[8][9]. SRC-family kinases illustrate the non-receptor mechanism, being activated downstream of many receptor classes and engaging shared and redundant effectors ^[17], while insulin-receptor signaling is organized around critical regulatory nodes that integrate and propagate the signal ^[18]. At the developmental level, knockout phenotypes for Flk-1 ^[4], Flt-1 ^[5], and Igf1r ^[6] map the non-redundant physiological outputs of individual RTKs onto vasculogenesis and growth.

5. Disease & therapeutic relevance

The therapeutic logic of this family is built on matching a kinase lesion to a targeted inhibitor. EGFR kinase-domain mutations in non-small-cell lung cancer (NSCLC) predict sensitivity to the inhibitor gefitinib ^[19], one of the founding examples of biomarker-driven oncology. Fusion oncoproteins are a recurring and highly druggable lesion: the EML4-ALK fusion defines a distinct NSCLC subset that is mutually exclusive with EGFR mutation and serves as both target and diagnostic marker ^[20], while the NPM-ALK fusion drives anaplastic large-cell lymphoma by linking a nucleolar protein to the ALK catalytic domain ^[21]. KIT gain-of-function mutations define gastrointestinal stromal tumors ^[16], JAK2 V617F underpins polycythemia vera and related myeloproliferative disorders ^[8][10], and BRAF mutation, although a serine/threonine kinase downstream of RTK-RAS signaling, anchors the broader RAS-RAF-MEK-ERK axis these receptors feed ^[22]. The newer disease genetics extend therapeutic interest beyond cancer, with JAK1 ^[7] and EPHB4 ^[11] implicated in immune and vascular disorders and AXL inhibition proposed as an antiviral approach ^[13].

6. Open questions & gaps

Several questions remain open within and beyond this corpus. First, the substrate is notably sparse on next-generation and later-line tyrosine kinase inhibitors and on the on-target resistance mutations that drive sequential drug development, so the contemporary resistance landscape cannot be characterized here. Second, recent high-resolution RTK ectodomain and full-length cryo-EM structures are absent, leaving the structural basis of ligand-induced activation underrepresented relative to its current activity. Third, the AXL entry-versus-immune-modulation controversy ^[13][14] shows that even receptor function assignments remain contested. Finally, whether the emerging non-oncologic indications, JAK1-driven immune disease, EPHB4 vascular malformation, CSF1R neurodevelopment, and RTK-mediated viral entry, will yield tractable kinase-inhibitor therapies is unresolved. These gaps mark the most fertile directions for tyrosine-kinase research over the coming years.